PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) reported today its accomplishments and financial results for the third quarter ended September 30, 2011.
“In the third quarter, we focused on completing the enrollment of our two Phase 3 trials of tavaborole, formerly known as AN2690, our topical antifungal product for onychomycosis, preparing for our End of Phase 2 discussions with the FDA for AN2728 in psoriasis, and completing our Phase 2a trial of AN2728 and AN2898 in atopic dermatitis,” said David Perry, CEO of Anacor Pharmaceuticals. “We have just completed enrollment in the first of the two tavaborole Phase 3 trials and are on track to complete enrollment in the second tavaborole Phase 3 trial by year-end 2011. We also successfully completed the End of Phase 2 discussions with the FDA about our Phase 3 development plans for AN2728 in psoriasis, and are on track to report Phase 2a data in atopic dermatitis by year-end. In addition, we amended and expanded our collaboration agreement with GSK and reached an important milestone in our animal health collaboration with Eli Lilly.”
“In the third quarter, we focused on completing the enrollment of our two Phase 3 trials of tavaborole, formerly known as AN2690, our topical antifungal product for onychomycosis, preparing for our End of Phase 2 discussions with the FDA for AN2728 in psoriasis, and completing our Phase 2a trial of AN2728 and AN2898 in atopic dermatitis,” said David Perry, CEO of Anacor Pharmaceuticals. “We have just completed enrollment in the first of the two tavaborole Phase 3 trials and are on track to complete enrollment in the second tavaborole Phase 3 trial by year-end 2011. We also successfully completed the End of Phase 2 discussions with the FDA about our Phase 3 development plans for AN2728 in psoriasis, and are on track to report Phase 2a data in atopic dermatitis by year-end. In addition, we amended and expanded our collaboration agreement with GSK and reached an important milestone in our animal health collaboration with Eli Lilly.”
